fashion -WSS

fashion

author：hotspot 2025-09-30 12:18:55 - browse：754

inflamed intestine on a dark blue background — biotech coverage from STAT — Adobe

What happens after you close a nearly $11 billion acquisition?

Well, for Prometheus Therapeutics’ former CEO Mark McKenna, there was a brief vacation. But within weeks of the company’s acquisition by Merck closing last June, he was thinking about ideas for the future.

Investors were floating ideas by him. McKenna discussed possibilities with his teenagers and Prometheus’ chief scientific officer. This “summer of discovery,” as McKenna called it, brought him back to the immune system. Prometheus and some other companies have been able to capitalize on creating treatments for conditions like inflammatory bowel disease and psoriasis, while arthritis medications like Humira have brought in billions of dollars in sales. But the field hadn’t quite received the same attention as missions to cure cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： 'Ancient DNA,' 23andMe reveal African American ancestries

focus

WSS

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Stories you might have missed in 2023: health, science, medicine

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Boston Scientific acquires urology company Axonics for $3.7 billion

For BCIs, commercial hurdles may be bigger than scientific ones

hotspot

fashion

focus

New air purifier tech could be key to improving indoor air quality

Medicare Advantage coverage denials need scrutiny, senators say

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Medicare details structure of new drug price negotiation program

White House drug shortage group privately met with industry

After affirmative action ruling, medical educators look to 'holistic review'

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Apple is now the first public company to be valued at $3 trillion

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

explore

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

For BCIs, commercial hurdles may be bigger than scientific ones

Stem cell clinics for heart failure: buyer be wary

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

STAT Virtual Event: JPM Recap, Live!

What the cancer research community can learn from the Covid response

hotspot

focus

leisure time

explore